Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAT2 genotype-guided isoniazid dosing to reduce DILI in slow acetylator tuberculosis patients
TCTR20210801005Phase 1Completed
- Sponsor
- Department of Medical Services
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of isoniazid in Tuberculosis (TB) (2 arms), sponsored by Department of Medical Services. Primary endpoint: Incidence of isoniazid-induced drug-induced liver injury (DILI). Started Feb 2018; status: completed.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on TCTR20210801005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210801005.